Your session is about to expire
← Back to Search
Mosunetuzumab for Non-Hodgkin's Lymphoma (MorningSun Trial)
MorningSun Trial Summary
This trial will test a new drug, mosunetuzumab, on patients with certain types of non-Hodgkin's lymphoma. They will be testing how effective and safe the drug is, as well as how it is processed in the body.
MorningSun Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMorningSun Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 59 Patients • NCT02034474MorningSun Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer type is confirmed by lab tests, I meet specific treatment history, kidney function, and lymphocyte count criteria.I have no severe allergies to antibodies, no PML, and no active COVID-19.I have had brain lymphoma or cancer spread to the lining of my brain and spinal cord.I haven't had CAR-T therapy, live vaccines, or certain immune-weakening drugs.I do not have any current infections.My cancer type is confirmed by lab tests, I have a specific treatment history, and my kidneys work well.I have been treated with mosunetuzumab before.My condition fits the specific requirements for Cohort C, including confirmed diagnosis and need for systemic therapy.I have no allergies or adverse reactions to lymphoma medications.I meet the age and specific diagnosis requirements for Cohort B.I have untreated follicular lymphoma and need to start treatment. My kidneys work well.I have a tumor that is larger than 1.5 cm or a lesion over 1.0 cm, confirmed by imaging.My blood counts are within normal ranges.I can take care of myself and am up and about more than half of my waking hours.I have tested negative for HIV or am stable on HIV treatment.I do not have a history of major health issues like autoimmune, CNS diseases, other cancers, uncontrolled diseases, liver diseases, recent surgeries, unresolved side effects from past treatments, or serious heart or lung problems.
- Group 1: Cohort E
- Group 2: Cohort B
- Group 3: Cohort C
- Group 4: Cohort D
- Group 5: Cohort A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently being welcomed into this clinical experiment?
"This research project necessitates 275 participants that fulfill the enrollment requirements. Genentech, Inc., is managing the trial with sites located in Medford, Iowa and Des Moines, Montana; namely Asante Rogue Regional Medical Center and Mission Blood and Cancer - MercyOne Cancer Center respectively."
What risks does Tocilizumab pose to individuals?
"Our team at Power judged Tocilizumab to be moderately safe by awarding it a score of 2, given that there are some safety studies in the Phase 2 stage but none demonstrating efficacy."
Are additional participants still being welcomed into this investigation?
"Clinicaltrials.gov reveals that this research is still in need of volunteers, with the initial posting taking place on February 1st 2022 and a recent edit made on November 8th 2022."
Has this trial been extended to multiple sites across the US?
"Currently, 36 locations are participating in this clinical trial. These sites span from Medford to Des Moines and Great Falls etcetera. To minimize the burden of traveling should you decide to take part, we recommend selecting a clinic that is closest to your home address."
Share this study with friends
Copy Link
Messenger